Essa Pharma Inc Reports Results For The Quarter Ended In June: Earnings Summary

ESSA Pharma

06/08/2024 13:21

* ESSA Pharma Inc  EPIX.OQ  reported a quarterly adjusted
loss
of 16 cents​​ per share for the quarter ended in June, higher
than the same quarter last year, when the company reported EPS
of -17 cents.  The mean expectation of five analysts for the
quarter was for a loss of 25 cents per share. Wall Street
expected results to range from -30 cents to -20 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * ESSA Pharma Inc's reported EPS for the quarter was a loss
of 16
cents​.
    * The company reported a quarterly loss of $7.23 million.
    * ESSA Pharma Inc shares had fallen by 12.0% this
quarter and
lost 29.8% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 15%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is  "buy."

Wall Street's median 12-month price target for ESSA Pharma Inc
is $17.00 
This summary was machine generated from LSEG data August 6 at
12:21 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.25          -0.16          Beat
 Mar. 31 2024      -0.19          -0.20          Missed
 Dec. 31 2023      -0.17          -0.14          Beat
 Sep. 30 2023      -0.21          -0.12          Beat